STIM1 and gastric cancer: Such a resistance mechanism to anti-EGFR therapy is not unique to Tam-R cells as it has also been shown in MKN7 gastric cancer cells that HRGs can overcome the growth inhibitory actions of the EGFR tyrosine kinase inhibitor CGP59326 through activation of downstream AKT and ERK1/2 signalling pathways [44].